Irbesartan + Hidroclorotiazida Sandoz

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Sandoz, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by helping to lower elevated blood pressure. GNH USA supplies Irbesartan + Hidroclorotiazida Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure and related cardiovascular conditions. - Essential hypertension: reduces systolic and diastolic pressure to target levels. - Secondary hypertension: assists in controlling blood pressure when caused by other medical conditions. - Hypertension in patients with diabetes: helps achieve blood pressure goals while providing renal protective benefits.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Increased urination or mild dehydration. - Electrolyte disturbances such as low potassium or sodium. - Headache. - Fatigue. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Acute kidney injury or worsening renal function. - Hyperkalemia, particularly when combined with potassium‑sparing agents. - Angioedema or severe allergic reactions. - Liver function abnormalities. - Blood disorders such as leukopenia or thrombocytopenia.

Before starting therapy, consider the following precautions: - Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Renal impairment: monitor kidney function and adjust dosage if necessary. - Electrolyte balance: check serum potassium and sodium regularly. - Concomitant diuretics: assess risk of excessive diuresis and electrolyte loss. - Gout: may increase serum uric acid; monitor patients with a history of gout. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment: risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - ACE inhibitors or other ARBs: additive blood pressure lowering and potassium rise. - Antidiabetic agents: may require dose adjustment due to enhanced hypoglycemic effect.